CONOGENETIX

Welcome to the Brand page for “CONOGENETIX”, which is offered here for Pharmaceutical preparations for the treatment of central and peripheral nervous system disorders, neurological disorders, cardiovascular and cerebrovascular disorders, neuromuscular discords, and demyelinating disorders, pain states, including acute and chronic pain, post-operative pain, neuropathic pain, inflammatory pain, and cancer pain; myocardial infarction, arrhythmia, heart failure, and stroke; multiple sclerosis; spinal cord injury; epilepsy; cancer; chemotherapy-induced nausea and vomiting;schizophrenia, depression, bipolar disorder, autism, attention deficit disorder, and addition; alzheimer's disease and parkinson's disease; traumatic head injury; and spasticity;.

Its status is currently believed to be active. Its class is unavailable. “CONOGENETIX” is believed to be currently owned by “Cognetix, Inc.”